🇺🇸

US SEC Filing Intelligence

· daily

General Federal Contracts — October 09, 2026

The 51 contracts in this October 9, 2026 digest aggregate $1,944,020,447 in total obligation, but the figure is dominated by a single $900,485,186 TriWest Healthcare Alliance VA delivery order that carries $0 outlayed and no visible recurrence, so headline value overstates durable revenue. None of the 51 awards are defense-related; the stream is entirely civilian, concentrated in VA facilities and construction (roughly a dozen awards), USDA Forest Service wildfire aviation (Neptune Aviation, Billings Flying Service, Helicopter Transport Services, ROTAK, HELI-1, AERO AIR), and DHS/CBP/USCIS IT and facilities work (Accenture Federal, Salient CRGT, Anduril, Spatial Front). The highest-materiality contract with actual execution evidence is the Accenture Federal CBP cybersecurity delivery order ($14,823,471 obligated against a $121,415,324 ceiling), while the largest outlay-backed awards are Neptune Aviation's airtanker orders (about 82-83% outlayed). Average signal strength is 3.1/10 and every contract is classified neutral, so the digest offers no directional call; the key watch item is whether the TriWest order and the 2026-era VA construction awards convert to outlays on schedule.

51 total filings
· daily

All NASA Contracts — October 09, 2026

Three NASA contracts totaling $99,268,494 in obligations were awarded or active in the period, with zero defense-related awards, making this a purely civilian space and facilities-energy snapshot. The largest is AMERESCO SELECT, INC.'s $48,129,004 firm-fixed-price energy-conservation delivery order at NASA Goddard (Wallops Island, VA), followed by SOUTHWEST RESEARCH INSTITUTE's $38,725,490 cost-plus-fixed-fee JUICE ultraviolet spectrograph work at NASA Marshall and California Institute of Technology's $12,413,999 cost-plus-fixed-fee delivery order from NASA JPL. The dominant theme is sustained NASA science and facilities spending, but the data does not establish agency budget trends. The highest-conviction read is the AMERESCO award's long-dated firm-fixed-price structure, though its parent's public-equity status is unverified. The key watch item is outlay progression: only about 42%, 16% and 17% of the respective obligations have been disbursed, so most value remains contingent on future funding and option actions.

3 total filings
· daily

S&P 500 Technology Sector SEC Filings — October 09, 2026

Across the 10 newly reviewed S&P 500 technology filings for 2026-10-09, the dominant theme is heavy insider selling by senior executives, concentrated among software, networking, and semiconductor names: Arista's CEO disposed of roughly $15M plus two smaller tranches, Analog Devices' Chief Operations/Tech Officer sold about $2.2M across two transactions, Datadog's CTO sold about $5.05M after option exercises, and Accenture's COO sold about $264K. Most of these sales were executed under Rule 10b5-1 plans, which dampens the signal value of any single transaction, though the clustering across companies in a single session is worth monitoring. The one substantive financial filing is Micron's 10-K for the fiscal year ended September 3, 2026, which reports revenue of $133,188M versus $37,378M in FY2025 (up 256%), net income of $84,969M versus $8,539M, gross margin expanding to 81% from 40%, and operating cash flow of $89,675M versus $17,525M. Micron's effective tax rate rose to 14.8% from 11.6% and interest expense fell to $106M from $477M after several debt tranches were repaid, while management supported an increase in authorized share repurchases. Gifting activity at Palo Alto Networks and NVIDIA and a board appointment at Cisco are governance items with limited direct market impact. The Micron filing is the materiality outlier, and the insider-selling cluster is the main sentiment counterweight.

10 high priority 10 total filings
· daily

Nasdaq 100 Stocks SEC Filings — October 09, 2026

The 2026-10-09 NASDAQ-100 SEC filing stream is dominated by one standout fundamental report: Micron Technology's FY2026 10-K, which shows revenue of $133,188M (up 256% from $37,378M), net income of $84,969M versus $8,539M, gross margin expanding to 81% from 40%, and operating cash flow of $89,675M, supporting a larger buyback authorization. Balance sheet deleveraging is evident, with senior note repayments through 2026 and interest expense down to $106M from $477M, though the effective tax rate rose to 14.8% from 11.6%. The remaining filings are governance and insider-activity items: Cisco added independent director Girish Rishi (committee assignments pending), NVIDIA's director made a 500,000-share gift under a 10b5-1 plan, and Analog Devices' COO/CTO Vivek Jain sold roughly $2.2M of stock across two transactions. Strategy Inc's DEFA14A is an incomplete excerpt with no substantive content and is excluded from quantitative analysis. Portfolio-level, the signal set is semiconductor-heavy and points to strong AI-cycle earnings power alongside modest, largely routine insider selling.

4 high priority 1 medium 5 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — October 09, 2026

This digest covers 50 Schedule 13D/13G and amendment filings for the 'Activist & Institutional Activity' stream, all dated 2026-10-09 with event dates clustered around September 30 and October 2026. The population is dominated by passive institutional disclosures under Rule 13d-1(b) and 13d-1(c): Wasatch Advisors LP alone appears in roughly 17 filings, and Calamos, Sachem Head, Glazer Capital and Frazier entities each contribute several more. Only a small number of filings reflect genuine control or activist intent, most notably Omnitek Engineering (Hard Rock Holdco, 85.2% reported beneficial ownership and a control purpose), Melco Resorts (Melco group at 62.6% with delisting/deregistration under evaluation), Gogoro (Gold Sino and Mr. Yin acquiring new shares at US$2.48 with closing by October 13, 2026), and Nexpu/Top KingWin (CEO at 90.71% voting power through Class B shares). The enriched period-over-period fields are largely absent in these filings: most report ownership percentages and voting-power splits rather than revenue, margin or guidance trends, so quantitative trend synthesis is limited and I have not manufactured comparisons. The clearest signals are concentrated control, insider-driven share accumulation, and a set of exits or reductions (Sotera Health full exit by Sachem Head; INVO Fertility reduction from 40,000 to 35,000 shares). Several filings are of low relevance to an activist or major-shareholder focus (routine passive holdings in closed-end funds, ETFs and SPAC warrants) and are treated with low materiality.

9 high priority 41 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — October 09, 2026

The stream covers three SEC filings dated 2026-10-09, but only two fall within the S&P 500 Financials scope: AFLAC Inc. and Robinhood Ventures Fund I, both reporting Form 4 insider sales by 10% owners. Both sets of sales were executed under Rule 10b5-1 plans, which reduces their informational weight as signals of management conviction. AFLAC's 10% holder Japan Post Holdings sold roughly $1.35M at $112.80 plus a small $4.54K tranche, leaving it with 50.38M shares, so the disposal is modest relative to its stake. Robinhood Markets sold about $353K across two tranches in Robinhood Ventures Fund I, leaving 12.96M shares. The third filing, a Morgan Stanley Capital I Trust 2016-UBS11 Form 15, is an asset-backed trust termination and is outside the S&P 500 Financials constituent list. Period-over-period comparisons and forward-looking guidance were not present in the enriched data for these filings, so no quantitative YoY/QoQ trend or catalyst can be drawn. The dominant theme is 10b5-1 monetization by large holders, with no evidence of broader sector stress or guidance revisions in this batch.

3 high priority 3 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — October 09, 2026

This Consumer Staples stream covers only two newly published filings for the 2026-10-09 window: a Hershey Form 4 showing continued 10b5-1 selling by the Hershey Trust, and an Altria 8-K extending its $3.0 billion revolving credit facility. Neither filing carries the period-over-period financial comparisons, guidance, or margin data the enriched schema promises, so portfolio-level trend analysis is not possible from this batch. The Hershey activity is the more market-relevant item: a 10% holder trust sold roughly 8,075 shares at about $162.42 (~$1.31M) across seven transactions, reducing its position to 616,119 shares, though the sales are pre-planned and the trust's selling is a structural diversification pattern rather than a directional call. The Altria amendment is administrative, pushing maturity from October 2029 to October 2030 with unchanged terms, signaling continued access to committed liquidity rather than any stress. Overall the batch offers limited actionable signal, and investors should treat the Hershey sales as a sentiment marker rather than a thesis change.

2 high priority 2 total filings
· daily

S&P 500 Industrials Sector SEC Filings — October 09, 2026

Six filings were reviewed for the USA S&P 500 Industrials stream; all six fall within scope. Delta Air Lines dominates the period: its September quarter 10-Q and 8-K show revenue growth of 21% YoY (GAAP) but operating margin compression to 7.2% from 10.1%, net income down 46.6%, and adjusted EPS of $1.72 flat YoY, as fuel prices rose 60% YoY to $3.61 per gallon and non-fuel unit costs rose 7.3%. Management guided Q4 2026 EPS to $1.15-$1.65 and full-year 2026 EPS to $5.10-$5.60 with roughly $2.5 billion of free cash flow, while nine-month operating cash flow fell 5.6% to $5,740 million. Delta's total debt and finance leases declined to $12,851 million from $14,112 million at year-end 2025, but current maturities rose to $3,324 million from $1,605 million, a near-term refinancing item to monitor. Premium and loyalty revenues (+18% each) are the clearest positive signals, indicating pricing power in the diversified revenue base. At 3M, four insider filings reflect routine equity vesting, tax withholding and option exercises at $162.12 per share by the CTO, Group President, and Chief Legal Officer, with no open-market selling evident; the implied insider sentiment is neutral. Norfolk Southern's only filing is a director's inheritance of 333.33 shares, which carries no signal. Overall the period is dominated by airline cost pressure, with fuel and labor costs offsetting strong top-line demand.

5 high priority 1 medium 6 total filings
· daily

US Material Events SEC 8-K Filings — October 09, 2026

Across the 50 filings dated October 9, 2026, the dominant themes are capital raising and balance-sheet management (ATM programs, registered directs, a $575M convertible from Vaxcyte, a $700M Atmos Energy senior note, Gray Media's refinancing and Term Loan G add-on), executive and director turnover (Avient CEO change, Quantum CFO termination, Standard Motor CFO exit, Victoria's Secret and Mitek senior departures), and corporate restructuring (MSG Sports Rangers spin-off, Evernorth/Armada business combination, Ranger Energy's $27.5M asset acquisition). Filings in the set largely lack quantified period-over-period results, so portfolio-level growth and margin trends cannot be computed reliably; the quantitative signal comes mainly from Atmos, Ashford, Alpine, Gray Media and Dentsply covenant data. Stress indicators cluster in micro-cap and SPAC names (Verde Resources auditor change with material weaknesses, Universal Safety's note financing exceeding its stated cap, Sunshine Biopharma's dilutive best-efforts deal) and in Dentsply's temporary covenant relief. Positive refinancing outcomes at Gray Media, McGraw Hill and Ares Commercial stand in contrast. The most market-moving items are the Evernorth/XRP business combination with its $6.9M unrecorded impairment exposure, Dentsply's covenant amendments, and Quantum's CFO change alongside a guidance reaffirmation.

50 high priority 50 total filings
· daily

Insider Trading Pulse — October 09, 2026

The 50 Form 4 filings dated 2026-10-09 are overwhelmingly routine insider activity: roughly 22 are director or officer equity awards, tax withholdings on vesting RSUs, or option exercises, with no clear open-market signal. The open-market sales that do stand out cluster in high-priced, momentum names (Astera Labs, Arista Networks, Marvell, Palo Alto Networks, Pacira, SailPoint), where 10b5-1 plan sales are the common mechanism and therefore carry limited information about near-term sentiment. The most notable open-market buying comes from Neogen's CEO, Mueller Water director Brian Healy, and Lion Copper & Gold director Tony Alford, all of which are small in dollar terms but are discretionary purchases. Pledge-related filings are absent from this batch, so the 'Pledge' scope element is effectively unrepresented. Several large dollar figures in the raw data (e.g., the INNSUITES and Empire State Realty entries) appear to be data-extraction artifacts rather than true transaction sizes and should be verified against the primary filings before use. Two filings (Amerant Bancorp, Security National Financial) are present in scope as insider trades but reflect minor, routine activity.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — October 09, 2026

This Dow Jones 30 digest covers six SEC filings dated October 9, 2026, five newly published and one carried forward for context. Five of the six are insider or governance disclosures from 3M, Walt Disney, NVIDIA and Cisco, and the set contains no reported period-over-period financial results, so there are no revenue, margin or guidance trend comparisons to synthesize. The dominant theme is routine executive equity compensation activity at 3M, where three officers exercised or had shares withheld for taxes at the same $162.12 price, which suggests scheduled vesting rather than a directional view. Disney's EVP Woodford sold $381K of stock under a 10b5-1 plan, a modest negative signal given the plan structure. NVIDIA's director gift of 500,000 shares and Cisco's board appointment of Girish Rishi are governance events with limited near-term market impact. Overall, the filings offer little actionable alpha; the most useful takeaway is that insider activity at 3M is uniform and non-discretionary-looking, while the Disney sale is the only transaction carrying a mild bearish read.

6 high priority 6 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 09, 2026

All five filings in this stream are distress-related, centered on US exchange listing deficiencies rather than bankruptcy filings or going-concern opinions. The common thread is Nasdaq and NYSE/NYSE American continued-listing enforcement: three companies face sub-$1 bid-price or equity-related deficiencies (Streamex, Accendra Health), and three face governance or filing-compliance failures (Better Home & Finance, IT Tech Packaging), with Alaunos already at the delisting-hearing stage. Because the enriched period-over-period, insider, capital-allocation and forward-looking fields were not populated in these filings, quantitative trend comparisons are not available; the analysis therefore rests on the explicit deadlines, notice dates and materiality ratings disclosed. The most critical development is Alaunos Therapeutics (materiality 8/10), where the October 5, 2026 delisting notice for sub-$2.5M stockholders' equity is now proceeding to a Hearings Panel with a strategic-alternatives process that carries no assured outcome. IT Tech Packaging (8/10) and Better Home & Finance (7/10) also carry near-term enforcement risk, while Streamex and Accendra have the longest cure windows (to April 2027 and roughly April 2027 respectively). Portfolio-level, the pattern is distress manifesting as exchange compliance pressure well ahead of any insolvency event.

5 high priority 5 total filings
· daily

Global High-Priority Regulatory Events — October 09, 2026

Across the 50 filings for the 'Global High Priority Market Events' stream dated 2026-10-09, the dominant theme is restructuring and control activity in Indian mid-caps and US small-caps: scheme-of-merger approvals (Lodha/National Standard/Roselabs), change-of-control events (Baba Arts, Skybridge), and multiple SPAC and micro-cap delisting or listing-compliance notices (Vestand, Alaunos, Better Home & Finance, Armada II, Plum IV, Launch Two). The most material single development is the Vireo Growth/Planet 13 S-4 merger (materiality 9/10), with the mixed picture of a fairness-opined cannabis combination. The most severe credit event is MTNL's default to seven public-sector banks totaling Rs 9,732 crore in current defaults against Rs 37,553 crore of total indebtedness, with all listed lenders now classified as NPA. Quantitative period-over-period data is sparse in this batch: most filings are procedural, so comparisons were drawn only where the disclosures supplied them (e.g., Triveni/TPTL, Hubtown/RTPL, ASI/Lloyds, Ashford pro forma). Several Indian approvals carried notable minority dissent or low public participation, which warrants scrutiny in the schemes. Overall the stream reads as a late-stage restructuring and delisting environment rather than a broad M&A wave.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — October 09, 2026

Today's filing set is dominated by M&A and capital-markets activity, with several large transactions in motion (C.H. Robinson/RXO, NextEra/Dominion, Medtronic's MiniMed separation, DSG's LKCM-backed going-private, First Bancorp/First Carolina, and GigCapital8/Quantisimo). Governance and shareholder-vote items are heavy, including multiple SPAC extensions and redemption windows, a SPAC-style deal structure with thin disclosure, and a DEF 14A cluster for Solidion. Financial performance data is sparse in most filings, so period-over-period evidence is limited, but the few quantified results point to a bifurcated picture: Huineng swung to nine-month profitability on a revenue surge while still losing money in the quarter, City Therapeutics' loss widened sharply, and OMA's September passenger traffic fell 4.8% YoY with domestic traffic down 5.9%. Healthcare and biotech signals were mixed to positive, led by Humana's Stars result that exceeds its Top Quartile goal and affirmed FY2026 Adjusted EPS of at least $9.00. A large cluster of 13F-HR filings (Shira Ridge, Ledgewood, DLK, Retireful, TLWM, Sunburst, Pioneer, M.E. Allison) reports ETF-heavy, passive-leaning portfolios with no prior-period comparisons, so they provide holdings context rather than directional signal. Overall, the day's market implications centre on deal-completion risk, shareholder-vote outcomes, and SPAC redemption dynamics rather than broad earnings momentum.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — October 09, 2026

This stream window contains a single filing from AutoZone, Inc. (AZO), an S&P 500 Consumer Discretionary constituent within scope. The 8-K discloses that director Claire R. McDonough informed the Board on October 6, 2026 that she will not stand for reelection at the 2026 Annual Meeting, citing a new executive role at another company whose calendar conflicts with future AutoZone board meetings. The filing explicitly states the decision was unrelated to any disagreement on operations, policies, or practices, and the Board said it would have preferred a different outcome. The filing carries a low materiality score of 3/10 and neutral sentiment. No period-over-period financials, forward-looking guidance, insider trading activity, capital allocation actions, or transaction details were included in the enriched data, so cross-company comparisons and quantitative trend analysis are not possible for this window. The implication is governance-housekeeping rather than fundamental: the event is a planned board turnover, not a distress signal. Investors should treat this as routine unless it is followed by a broader board refresh or disagreement disclosure.

1 high priority 1 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — October 09, 2026

Four SEC filings were reviewed for the USA S&P 500 Healthcare stream, all dated October 9, 2026. Three of the four are in scope: Humana (8-K), Medtronic (two Rule 425 filings), and Cigna Group (8-K). The dominant development is Humana's disclosure that its 2027 Medicare Advantage Star Ratings (Bonus Year 2028) exceed its Top Quartile goal, with management affirming FY 2026 Adjusted EPS guidance of at least $9.00 and signaling that part of the BY28 outperformance will be one-time and redeployed into investments and shareholder returns. Medtronic's filings describe an exchange offer for up to 225,361,295 MiniMed Group shares in exchange for Medtronic common stock as part of a MiniMed separation, but neither filing discloses an exchange ratio, valuation, or financial results, so the market impact cannot yet be sized. Cigna's 8-K is a routine board retirement with no financial implications. The provided enriched data contains no period-over-period financial comparisons, insider transaction records, capital allocation figures, or ratio data, so trend-based synthesis across peers is not supportable from these filings and conclusions are limited to disclosed events and guidance language.

3 high priority 1 medium 4 total filings
· daily

US Earnings Financial Results SEC Filings — October 09, 2026

Across 14 US SEC filings for the period ending around August 31, 2026, results are broadly mixed: several companies show strong top-line or earnings momentum while balance sheets, cash burn, and going-concern dependence remain pressing concerns for the smaller issuers. The large-cap signals are the most material. Micron's FY2026 10-K shows revenue up 256% to $133.2B, gross margin expanding to 81% from 40%, and an upsized buyback authorization, the clearest positive datapoint in the group. Delta's Q3 shows revenue up 21.1% YoY to $20.2B but net income down 46.6% as operating expenses (+25.0%) outran revenue and fuel costs spiked, compressing operating margin to 7.2% from 10.1%. Jefferies posted revenue +11.1% and net earnings +18.9%, yet non-interest expenses (+9.1%) outpaced net revenue (+8.5%) and interest expense (+17.3%) outgrew interest income (+9.0%). Among the shell, SPAC, and micro-cap names, a recurring pattern is trust-driven or non-operating income (SPAC trust interest, Harbor's $14.9M asset-sale gain, GHST's $35K other income) masking weak operations, with deficits widening across Quartzsea, Iron Horse II, alpha-En, and GHST. Overall, the market implication is a bifurcation: AI/memory and selective industrial strength versus fragile micro-cap and shell balance sheets.

14 high priority 14 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 09, 2026

This digest covers 22 DEF 14A and DEFM14A filings for the 'Executive Compensation Insights' stream, centered on annual proxy statements, governance, and shareholder proposals. The filings are dominated by routine governance mechanics (director elections, auditor ratification, say-on-pay votes), with very few supplied with quantitative period-over-period financial data. The most substantive financial disclosures come from Coherent Corp. (record FY2026 revenue of $7.12B, up 22.5% YoY, GAAP gross margin up 233 bps to 37.5%), Sezzle (2025 net income $133.1M, up 70% YoY), and Performance Food Group (qualitative growth claims with no specific figures). The highest-materiality situations are corporate-action votes rather than compensation items: XWELL's airport-business sale with an unquantified arbitration exposure, and Newbury Street II's SPAC extension where post-redemption trust balances may fall far below the ~$186.9M held. Shareholder-dilution and capital-structure proposals (Envirotech's reverse split and preferred conversion, International Battery Metals' up-to-1-for-50 consolidation, Solidion's 975,000-share plan increase) cluster as a theme. Executive compensation disclosure is largely absent from the excerpts, which limits direct pay analysis and insider-activity signals. Overall, the stream's information content is thin, so the most actionable items are the time-sensitive votes and redemption deadlines.

22 high priority 22 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 09, 2026

Across the 11 filings for the IPO Pipeline stream (all dated 2026-10-09 or the immediately preceding window), the dominant theme is capital formation under strain: a small-cap IPO (Simwon America), a going-concern biotech resale registration (GT Biopharma), a capital-hungry bridge-loan-funded issuer (Cyabra), a distressed warrant overhang (BIO-key), and a convertible-debt-laden filer (Specificity) all surface alongside a clinical-stage biotech IPO (Aspen Neuroscience, Bambusa) and two SPAC or M&A-driven listings (Plus Automation via Texas Ventures III; Vireo/Planet 13 and DTI/Saltire). Period-over-period comparison data is thin across this batch: several excerpts omit revenue, margin, or net income figures entirely (Simwon, Aspen, Patriot Mobile, Specificity, Plus Automation), so cross-company growth or margin comparisons cannot be made reliably and should be treated as a data gap rather than a signal. Where quantitative anchors exist, they point to dilution and financing pressure rather than growth: GT Biopharma's 1-for-25 reverse split cut shares outstanding from 45.1M to 1.8M, BIO-key's inducement repriced warrants from $10.20 to $4.06, and Cyabra is explicitly reliant on bridge and convertible financing. Insider signals are largely absent from the excerpts, so management conviction cannot be assessed from this batch. The most market-relevant developments are the Vireo/Planet 13 merger (materiality 9/10), the Plus Automation SPAC combination with redemption scenarios, and the DTI acquisition requiring a Nasdaq 5635(a) shareholder vote. Net implication: the IPO window is open for selectively credible names, but this batch skews toward financing-dependent issuers where dilution risk outweighs the offering narrative.

11 high priority 11 total filings
· daily

US SEC Trading Suspension Halt Orders — October 09, 2026

All five filings in this stream are negative-sentiment regulatory notices concerning US listing compliance rather than trading halts themselves: four involve Nasdaq or NYSE/NYSE American deficiency or delisting notices (minimum bid price, stockholders' equity, board governance, and late SEC filings), and none of the five has an immediate suspension in effect. The dominant theme is sub-$1.00 price and equity-deficiency pressure in small-cap issuers, with two companies (Streamex and Accendra Health) facing bid-price deadlines and one (Alaunos) facing an active delisting process that is stayed pending a Hearings Panel. Governance breakdown (Better Home & Finance) and reporting failure (IT Tech Packaging) show that non-price compliance failures are also driving exchange actions. The enriched fields for period-over-period financials, insider activity, forward-looking guidance, and capital allocation are largely absent from these notices, so the analysis rests on the regulatory timelines and deadlines disclosed. Market implication: the clearest near-term risk events are the Alaunos hearing and the Better Home compliance-plan deadline, while the longer-dated deadlines (April 2027) mainly signal potential reverse splits and dilution.

5 high priority 5 total filings